Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Policy Effort Adjusts To Obama Era: Adds Greg Simon, From Obama Transition

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer is aligning its internal policy shop to get more in tune with Democratic Washington. The first major staff change is Greg Simon moving from Faster Cures advocacy group to become senior VP-worldwide policy.

You may also be interested in...



Biotech Equity Crowdfunding Gets A Head Start Overseas

Can crowdfunding fill the biotech capital gap? In the US, new services are jockeying at the starting gate even though the government’s final rules won’t be ready soon, while in Europe the experiment has begun in earnest.

PhRMA Has Labor Support For Extended Biologics Exclusivity

The Sheet Metal Workers' International Association labor union supports the 12-year data exclusivity for biologics embodied in Sen. Edward Kennedy's follow-on biologics bill

US Price Negotiation Hearing Lays The Groundwork For Future Improvements

The pharma industry is hoping that litigation might end Medicare price negotiation before it begins. But a House hearing also starts the process of developing legislative improvements that might be viable in years to come – starting with trying to restore the lifespan of small molecules.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS069416

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel